A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects. by Mohammad, Jaber et al.
UCSF
UC San Francisco Previously Published Works
Title
A Controlled Increase in Dietary Phosphate Elevates BP in Healthy Human Subjects.
Permalink
https://escholarship.org/uc/item/8dp4t9gj
Journal
Journal of the American Society of Nephrology : JASN, 29(8)
ISSN
1046-6673
Authors
Mohammad, Jaber
Scanni, Roberto
Bestmann, Lukas
et al.
Publication Date
2018-08-01
DOI
10.1681/ASN.2017121254
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BASIC RESEARCH www.jasn.org
A Controlled Increase in Dietary Phosphate Elevates
BP in Healthy Human Subjects
Jaber Mohammad,1 Roberto Scanni,1 Lukas Bestmann,2 Henry N. Hulter,3 and Reto Krapf4
1Department of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland; 2Bioanalytica Labs/Medisupport,
Lucerne and Zurich, Switzerland; 3Department of Medicine, University of California San Francisco, San Francisco,
California; and 4Department of Medicine, University of Basel, Basel, Switzerland
ABSTRACT
Background Despite epidemiologic evidence for increased cardiovascular morbidity and mortality asso-
ciated with both high dietary and serum phosphate in humans with normal renal function, no controlled
phosphate intervention studies of systemic hemodynamics have been reported. Higher serum 25(OH)
vitamin D levels are associated with better cardiovascular outcomes, but vitamin D increases intestinal
phosphate absorption.
MethodsWe conducted a prospective outpatient study with blinded assessment in 20 young adults with
normal renal function randomized to high phosphate (regular diet plus 1mmol/kg bodywt per day ofNa as
neutral sodium phosphate) or low phosphate (regular diet plus lanthanum, 750 mg thrice/day, plus 0.7
mmol/kg body wt per day of Na as NaCl) for 11 weeks. After 6 weeks, all subjects received vitamin D3
(600,000 U) by intramuscular injection. Outcome parameters were 24-hour ambulatory systolic and dia-
stolic BP (SBP and DBP), pulse rate (PR), biomarkers, and measures of endothelial and arterial function.
Results Compared with the low-phosphate diet group, the high-phosphate diet group had a signiﬁcant
increase in mean6SEM fasting plasma phosphate concentration (0.2360.11 mmol/L); 24-hour SBP and DBP
(14.1; 95% conﬁdence interval [95% CI], 2.1 to 6.1; and13.2; 95% CI, 1.2 to 5.2 mmHg, respectively); mean
24-hour PR (14.0; 95% CI, 2.0 to 6.0 beats/min); and urinary metanephrine and normetanephrine excretion
(54; 95% CI, 50 to 70; and 122; 95% CI, 85 to 159 mg/24 hr, respectively). Vitamin D had no effect on any of
these parameters.Neither high- nor low-phosphate diet nor vitaminD affected endothelial function or arterial
elasticity.
Conclusions Increasedphosphate intake (controlled for sodium) signiﬁcantly increases SBP,DBP, and PR in
humans with normal renal function, in part, by increasing sympathoadrenergic activity.
J Am Soc Nephrol 29: 2089–2098, 2018. doi: https://doi.org/10.1681/ASN.2017121254
Vascular calciﬁcation is a cardiovascular risk factor
leading to increasedmortality inbothCKDandgeneral
populations.1 Both traditional (hypertension, diabetes,
dyslipidemia) and nontraditional risk factors (inﬂam-
mation, oxidative stress, advanced glycation end prod-
ucts, hyperphosphatemia, elevated FGF-23 levels)2 are
important in inducing vascular calciﬁcation. Elevated
extracellular phosphate concentration has been found
in observational epidemiologic assessments to play a
highly suggestive role in initiating and exacerbating
vascular disease and cardiovascular mortality in pa-
tients with CKD.3,4
The negative effect on cardiovascular
morbidity/mortality of high dietary phosphate
load/hyperphosphatemia may, however, also affect
the general population5,6:
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The age-associated decrease in GFR could contribute to a
slowly progressive increase in net phosphate load per
nephron and associated incremental hyperphosphatemia,
but such experiments would require accurate measured
GFR and control of diurnal phosphate sampling time
effects.
Mostly because of its use in processed “fast foods,” phosphate
intake has risen in recent decades and is now far above the
current recommended daily allowance for inorganic
phosphate as established by the National Academy of
Medicine (700 mg).
Independent associations of fasting plasma phosphate con-
centration and dietary phosphate loads with cardiac calci-
ﬁcation, left ventricular hypertrophy, cardiovascular events,
and death are evident in the general population, even in
younger adults, and cardiovascular event risk accelerates
with phosphate levels .1.15–1.47 mmol/L.7–11
1,25(OH)2D stimulates intestinal phosphate absorption,
thereby increasing the systemic phosphate load.12 Lower 25
(OH) vitamin D levels or decreased supply of dietary vita-
min D are associated with increased cardiovascular mor-
bidity and cardiovascular as well as all-cause mortality.13–16
Therefore, it is unclear whether the routinely recommended
vitamin D supplements might protect against cardiovascular
phosphate toxicity or aggravate it via increasing phosphate
absorption.
We examined in young healthy subjects with normal renal
function, by randomized single-blinddesign, the effects of low-
phosphate (LP) and high-phosphate (HP) intake for 6 weeks
on a variety of cardiovascular hemodynamic effects (i.e.,
24-hour BP and pulse proﬁles and measures of endothelial
and arterial function) and cardiovascular risk and aging markers,
as well as phosphate homeostasis. In addition, we evaluated the
effect of supplemental vitamin D3 on these parameters with con-
tinued LP and HP intake for another 5 weeks.
METHODS
Study Protocol
We evaluated the chronic effects of decreasing and increasing
the dietary phosphate load without and with vitamin D3 supple-
mentation on cardiovascular outcome parameters, i.e., 24-hour
systolic and diastolic BP (SBP and DBP) and mean pulse rate,
reactive hyperemia index as a measure of endothelial function,
and aortic pulse wave velocity (PWV) and the augmentation in-
dex (AI) as a measure of arterial elasticity.
In a prospective, exploratory, single-blind outpatient study
design (see Figure 1), 20 young, healthy human subjects of
both sexes were studied. Exclusion criteria were: any evidence
for kidney disease; electrolyte or acid-base disturbance; ofﬁce
BP$125/80 mm Hg; ingestion of any drug (prescribed, over
the counter, or illicit) during the 3 months before and during
the study; smoking; excessive alcohol intake (more than
1 drink/d); any evidence for adrenal (24-hour urinary cortisol
and aldosterone excretion), thyroid, or parathyroid dysfunction;
or 25(OH)D serum concentrations,50 or.100 nmol/L.
The subjects were randomized by a research administrator,
unblocked, and unstratiﬁed 1:1 to either theHP group (n=10),
ingesting regular diet plus 1 mmol sodium per kg body weight
per os as neutral sodium phosphate (yielding 0.55 mmol P per
mmol Na) in three divided doses per day with meals, or to the
LP group (n=10), ingesting a regular diet and the intestinal
phosphate binder lanthanum (Fosrenol, 750 mg; Shire Phar-
maceuticals, Lexington,MA, in three per os divided doses with
meals). The LP group was supplemented with 0.7 mmol/kg
body wt per day NaCl commensurate with the excess sodium
intake of the HP group assuming an intestinal absorption of
sodium phosphate of 70%.17 After 6 weeks of LP or HP load-
ing, all subjects received a single intramuscular injection of
vitamin D3 (600,000 U) and were studied for another 5 weeks.
There were three visits each on three consecutive days at base-
line, at the end of week 6, and at the end of week 11 (5 weeks
after vitamin D administration). There were additional visits
every 2 weeks to assess tolerance, safety, and compliance and a
close-out visit at the end of week 12. After study unblinding,
the HP group was re-examined (24-hour ambulatory BPmea-
surement [ABPM] and tests of endothelial and arterial func-
tion only) in a recovery visit on regular diet 2 months after the
close-out visit.
Figure 1. Flowchart of study protocol. Each arrow denotes daily
complete assessments (three consecutive days/evaluations per
study period). F/U, follow-up; La, lanthanum; NaCl, sodium
chloride; NaP, neutral sodium phosphate; RD, regular diet.
Signiﬁcance Statement
Dietary intake of phosphate has increased signiﬁcantly in recent
years mostly due to increased intake of processed food. Despite
strong epidemiologic evidence for increased cardiovascular mor-
bidity and mortality associated with increased dietary phosphate
intake in healthy humans, no intervention studies with controlled
phosphate intakehavebeen reported. This exploratory, physiologic
study shows that a controlled increase in dietary phosphate (within
the range observed in a representative United States population)
signiﬁcantly and reversibly increases BP and pulse rate in young,
healthy human adults. The effect is associated with a phosphate-
speciﬁc increase in sympathoadrenergic activity. These results
provide an important explanation for the association of dietary
phosphate intake with increased cardiovascular morbidity and
mortality in the general population. These conclusions, if supported
by larger studies in diverse populations, are of public health
importance.
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Measurements
Twenty-four-hour ABPMs were made at the nondominant arm
using thecommercialSchillerBR-102devicewithvendor software.
BP measurements were made every 15 minutes (06:00–22:00
hours) and every 30 minutes during the nighttime (22:00–06:00
hours), consistent with ABPM method guidance.18
Arterial pressure waveformswere recorded and analyzed using
establishedtechniquesusingvendorsoftware(Sphygmocor;AtCor
Medical, Australia). In brief, the aortic PWV (m/s) is estimated by
calculating the time between the foot of the pressure wave and the
inﬂection point. Augmentation represents the difference between
the second reﬂected systolic peak and ﬁrst systolic peak of the
central pressure waveform, and AI is deﬁned as the augmentation
increment expressed as a percentage of the pulse pressure and is a
measure of systemic arterial stiffness.19
Endothelial function was analyzed by determining the reactive
hyperemia index, measured as ﬂow-mediated vasodilation after
5 minutes of tourniquet-induced hypoxia using the Endopat
(Itamar, Israel) pulse arterial volume change as assessed with a
ﬁngertip sensor and vendor software. The tourniquet was applied
to the dominant arm and ﬁnger probes to both hands, the non-
dominant side serving as control.
Before these measurements, the fasting subjects were lying
comfortably for 30minutes in a noise-shielded, dimly lit room,
at a constant room temperature of 22°C–24°C and constant
humidity of 58%–62%.Measurements were always performed
between 08:30 AM and 11:00 AM. In our
study lab, the interassay coefﬁcient for
PWV measurements was 5.9%, and 8.7%
for reactive hypoxia index.
Biochemical Analysis
Fasting samples for plasma electrolyte and
blood acid-basemeasurements and for serum
endocrineandagingmarkersweredrawnafter
preheating the forearm to 43°Cwithout use of
tourniquets between 07:00 AM and 08:00 AM.
Twenty-four-hour urines (three consecutive
days of each study period) were collected un-
der parafﬁn oil with thymol as a preservative.
Plasma and urine electrolytes were measured
in the hospital routine lab.
1,25(OH)2D was measured by ELISA
(Immundiagnostik AG, Bensheim, Ger-
many), 25(OH) vitamin D by the liquid
chromatography–mass spectrometrymethod
(MassChrom), and intact PTHand insulin by
the Unicel Dxl 800 immunoassay system
(Beckman Coulter).
Human FGF-23 (second generation, dual
antibody method to detect both C-terminal
and intact FGF-23) was measured using an
ELISA kit (#60–6100; Immunotopics, San
Clemente, CA). Serum aKlotho protein was
precipitated from the serum using the sb-106
Fab, reported to recognize both vector HEK cell–expressed hu-
man full-length membrane Klotho (Isoform 1; Uniprot Consor-
tium, Switzerland) and Klotho extracellular domain (ECD)
(a cut) as nominal 130-kD bands. After gel electrophoresis, the
immune-precipitated aKlotho protein was further detected on
immunoblot using the clone KM2076 antibody (Transgenic
Inc.,Kobe, Japan).This antibodywas generated fromKL1domain
immunization in rats andwas reported to detect (western blot) an
approximately 130-kD human renal membrane-associated
klotho and thus may detect human full-length membrane klotho
(Isoform1), proteolytic ECD (a cut) near 130 kD, or the secreted
alternatively spliced isoform at a lower molecular mass (Isoform
2; Uniprot).20,21 KM2076 is predicted to not detect a putative C
terminus b cut Klotho (KL2 domain). The serum 130 kD band
was estimated on the basis ofmurine rKlotho isoform1 standard
as a density and thus likely represents thea cut protein ECD.The
rKlotho protein standardwas obtained fromaCHOcell line that
stably expressed the full-length Klotho (CHOKL, Isoform 1),
obtained as a gift from Kyowa Hakko Kogyo Co. Ltd.22
Urine Klotho was measured by adding urine to 43 lithium
dodecyl sulfate sample buffer containing a ﬁnal concentration of
100mMdithiothreitol. The boiled sampleswere runon a 4%–14%
Bis-Tris gel (NuPage; Invitrogen), immunoblotted using clone
KM2076 antibody, and reported as density of the 130-kD band.
Plasma renin and aldosterone andurinary aldosterone concen-
trations were measured by chemiluminescence immunoassay
Figure 2. High phosphate diet increases FGF-24, PTH, and both plasma and urinary
Klotho, while low phosphate diet has no effect. (A) Effect of HP diet: Baseline (RD),
after 6 weeks of HP diet (RD+NaP), and 5 weeks after supplemental vitamin D3
(600,000 U in one single intramuscular dose) and continued HP diet. (B) Effect of LP
diet: Baseline (RD), after 6 weeks of ingestion of the phosphate binding substance
lanthanum (750 mg per os three times a day) with supplemental NaCl, and 5 weeks
after supplemental vitamin D3 (600,000 U in one single i.m. dose) and continued
lanthanum and NaCl administration. *P at least ,0.05 compared with baseline (RD).
La, lanthanum; NaCl, sodium chloride; NaP, neutral sodium phosphate (0.55 mmol/kg
body wt phosphate per day); PTH, parathyroid hormone; RD, regular diet.
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(Bioscientia, Ingelheim, Germany). Urinary total metanephrine
and normetanephrine (comprising free and conjugated com-
pounds) were measured by HPLC after acid hydrolysis, and uri-
nary free cortisol was measured by liquid chromatography–mass
spectrometry.
The serum calciﬁcation propensity test (T50) was performed
using a Nephelostar nephelometer (BMG Labtech, Offenburg,
Germany).23 Serum oxidized LDL and SOD1 were measured by
ELISA, antioxidative capacity and serum lipid peroxide concen-
trationweremeasuredphotometrically, andurinary8-oxo-2-deoxy
guanosine was measured by ELISA (all: Biovis, Limbur, Offheim,
Germany).
After enrollment, subjects received advice to ingest a stable
self-selected diet.
All values given in “Results” are the means of three mea-
surements made on these three separate, consecutive days in
each period.
Investigators were blinded to treatment assignment of each
study subject throughout the study.
The protocol was approved by the ethics committee of both
Cantons of Basel (Switzerland).
Methods and safety considerations of the vitamin D dosing
are described in the Supplemental Material.
Statistical Analyses
Sample size determination was empiric without consideration
of power or effect size. Values given are means with 95% con-
ﬁdence intervals (95% CIs) for the cardiovascular outcome
parameters. All other values are mean6SD or SEM, as indi-
cated. Statistical signiﬁcance was tested with ANOVA for re-
peatedmeasures for intragroup comparison andwith one-way
ANOVA for intergroup comparisons.
RESULTS
Study population: 53 human subjects were screened and 20were
included into the study at 1:1 randomization (HP group/LP
group). All randomized subjects completed the study. Reasons
for exclusion were: Loss of interest in participation due to occu-
pational duties (n=9), study perceived as too long and too de-
manding (n=21), vitamin D deﬁciency (n=1), and concomitant
medications (n=2). Subject characteristics are listed in Supple-
mental Table 1. Compliance rate (inspection of unused agents)
for the ingestion of oral study drugs (NaPO4, lanthanum, and
NaCl) was 96% in the HP group and 95% in the LP group.
HP induced a signiﬁcant intra- and intergroup rise in fasting
plasma phosphate concentration (+0.1960.09 mmol/L,
P=0.03, Figure 2A, Table 1) and 24-hour mean urinary phos-
phate excretion rate (+21.067.2 mmol/24 hr, P,0.01, Table
2). Neither value was further affected signiﬁcantly by the D3
supplement. The LP diet’s lanthanum supplement decreased
urinary phosphate excretion nonsigniﬁcantly (25.962.3
mmol/24 hr) without affecting fasting plasma phosphate con-
centration. In contrast to HP, D3 in the LP group increasedT
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urinary phosphate excretion signiﬁcantly (+6.863.1mmol/24
hr, P=0.04). Table 2 also shows that 24-hour urinary sodium
excretion rates were not different among HP and LP groups,
conﬁrming the protocol’s intent for a similar daily sodium
load throughout the study among both groups.
Figure 2, A and B, and Table 3 show that HP induced signif-
icant intra- and intergroup increases in the serum concentra-
tions of PTH, FGF-23, and aKlotho and urinary Klotho,
whereas LP without and with D3 had no effect. In response to
vitamin D3, serum 25(OH)D and 1,25(OH)2D increased signif-
icantly in both groups, whereas mean serum PTH and FGF-23
decreased in the HP group. Both PTH and 1,25(OH)2D have
been shown to increase FGF-23 serum concentration.24,25 The
baseline values for urinary phosphate excretion of approxi-
mately 21 mmol/24 hr are similar to reported United States
and European subjects on self-selected diets.26,27
Figure 3A and Table 4 illustrate that HP induced signiﬁcant
inter- and intragroup increases in bothmean 24-hour SBP and
DBP and mean 24-hour pulse rate, whereas LP had no effect.
HP increased 24-hour mean SBP by +4.1 mmHg (95%CI, 2.1
to 6.1), 24-hour mean DBP by +3.2 (95% CI, 1.2 to 5.2) mm
Hg, and mean 24-hour pulse rate by +4.0 (95% CI, 2.0 to 6.0)
beats/min. Because these increases were resistant to further
change by supplemental vitamin D3, subjects in the HP group
were restudied and reversibility of short-term dietary phosphate–
induced increases in BP and pulse rate was documented. Figure
3B shows the circadian rhythm of mean arterial pressure.
Sympathoadrenergic activity, as assessed by 24-hour urinary ex-
cretion of metanephrine and normetanephrine, was stimulated
by HP: Urinary metanephrine and normetanephrine excretion
increased by 54 (95% CI, 28 to 70) and 122 (95% CI, 85 to 159)
mg/24 hr, respectively, whereas 24-hour urinary excretion rates
of aldosterone, free cortisol, and plasma renin/aldosterone con-
centrationwere not affected by eitherHPor LP (Figure 3A, Table
4). Figure 3C shows a scatter plot of the individualmean 24-hour
arterial BP changes in the HP group.
As illustrated in Table 5, in both HP and LP groups without
and with vitamin D, no measurable effects on endothelial
function and/or arterial elasticity were found.
With the exception of increases in lipid peroxide serum con-
centrationandurinaryexcretionrateof8-oxo-2’-deoxy-guanosine,
modulation of dietary Pi loading did not affect markers of cardio-
vascular risk, oxidative stress, and senescence (Table 6).No adverse
events were reported.
DISCUSSION
These are—to our knowledge—the ﬁrst reported hemodynamic
data from a prospective dietary phosphate interventional study in
humans with normal renal function. The principal ﬁnding is that
increasing the systemic phosphate load by an amount sufﬁcient to
signiﬁcantly increase fasting plasma phosphate concentration in-
duces signiﬁcant increases in both SBP and DBP as well as pulse
Table 2. Twenty-four-hour urinary excretion rates of electrolytes, creatinine, and albumin in HP and LP groups without and
with vitamin D3 at baseline, W6, and W11
Period/Group Na+ K+ Cl2 Ca Pi Mg Creatinine Albumin (mg/24 h) Body Weight (kg)
HP baseline 11968 5564 10668 3.460.2 20.562.2 3.360.3 7.861.1 5.262.2 64.565.6
LP baseline 11767 5365 10767 3.360.2 21.962.4 3.260.4 7.661.2 5.362.4 63.764.8
HP W6 145a69 5966 9766 2.860.1 41.5b64.1 3.260.2 7.161.0 3.462.3 65.165.8
LP W6 149a68 5265 139c68 3.160.3 14.661.8 3.360.2 7.161.2 5.062.5 64.564.4
HP plus D3 W11 142
a610 5964 10267 3.060.2 42.5b63.4 3.360.3 6.560.9 4.362.6 64.665.1
LP plus D3 W11 149
a69 5765 133c67 3.060.2 21.4d62.9 3.360.2 6.660.9 2.562.4 64.464.5
Data are mean6SD, values are millimoles (milliequivalents per 24 h unless indicated otherwise). HP, HP group; LP, LP group; W, week.
aP,0.03 compared with own baseline.
bP,0.01 for intra- and intergroup comparisons.
cP,0.02 compared with own baseline.
dP=0.04 for comparison of LP plus D3 to LP without D3.
Table 3. Mean serum concentrations of phosphate-regulating hormones and urinary excretion of Klotho under HP and LP
dietary conditions without and with supplemental D3
Group/Period
Serum 25(OH)D
(nmol/L)
Serum 1,25(OH)2D
(pmol/L)
Serum iPTH
(pg/ml)
Serum FGF-23
(pg/ml)
Serum aKlotho
(pmol/L)
Urinary aKlotho
(ng/g Creatinine)
HP baseline 63.066.4 92.468.1 41.464.8 21.263.8 24.663.7 7.961.8
LP Baseline 63.567.4 93.768.4 41.863.9 21.362.9 24.662.9 7.261.5
HP W6 68.365.8 89.169.9 51.7a66.2 31.4a63.6 45.0a65.2 12.6a63.0
LP W6 67.367.6 99.4610.4 42.464.4 19.162.4 31.664.6 7.161.3
HP plus D3 W11 113.6
b612.4 141.6b615.2 41.3c64.5 23.1c63.6 32.0c64.7 7.862.0
LP plus D3 W11 104.9
b614.2 132.9b614.8 43.165.2 22.863.0 31.864.4 6.261.3
Values are mean6SEM. iPTH, intact parathyroid hormone; HP, high phosphate group; LP, low phosphate group; W, week.
aP,0.02 compared with own baseline, and ,0.025 for comparison to LP group.
bP,0.01 in comparison with baseline and HP/LP without D3 supplementation.
cP,0.03 for the comparison of HP without to HP with D3 supplemented.
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rate. The effect is experimentally speciﬁc to the ingested phos-
phate because the subjects were well controlled for the increase in
sodium load. These results are in accordance with all but one28
report in normotensive and spontaneously hypertensive rats
(both with normal renal function), that an HP diet elevated BP
and augmented the exercise pressor reﬂex function.29–31 Our
studies also offer an explanation—at least in part—of the mech-
anism of the phosphate-induced hypertensinogenic effect:
Although plasma renin/aldosterone concentrations and 24-hour
excretion rates for both aldosterone and free cortisol were un-
changed, 24-hour urinary excretion rates of metanephrine and
normetanephrine increased signiﬁcantly, explaining the addi-
tional observation of signiﬁcantly increased mean 24-hour pulse
rate. Even small increases in sympathetic nervous system activity
may be sufﬁcient to cause signiﬁcant hypertension because anHP
diet in mice has been reported to potentiate phenylephrine-
induced vasoconstriction in ex vivo aortic rings.32 In addition,
increased extracellular phosphate concentration, per se, has also
been demonstrated to result in vasoconstriction in murine aortic
rings in vitro.33 It will be of interest to investigate whether phos-
phate exerts its sympathetic effect via a primary central or periph-
eral stimulation of the sympathetic nervous system and
whether the effect of phosphate is direct ormediated via unknown
endocrine/paracrine factors that are modulated by phosphate in-
take. The ﬁnding of increases in both PTH and FGF-23 in the HP
group, yet persistence of the hypertensinogenic and heart rate ef-
fectswhenPTHand FGF-23 levels hadnormalized, suggests that at
least those effects in tandem may not be pivotal hemodynamic
mediators for the present results.
Thebasis for sympathetic activationby anHPdiet remains to be
determined. One potential mechanism for phosphate-induced
sympathetic activation is the presence of phosphate-responsive
NaPi2-like transporters in the rat amygdaloid region of the central
nervous system as identiﬁed by immunocytochemistry.34 Infusion
of very low (20 nM) phosphate concentrations into the third
ventricle resulted in a profound suppression of NaPi-2 protein
expression as compared with vehicle perfusion, providing at least
an afferent arm for potential systemic phosphate effects on brain/
sympathetic function.
Figure 3. HP diet increases mean 24-hour SBP, DBP, and pulse
rate with preserved circadian oscillation, and in parallel with
signiﬁcant increases in urinarymetanephrine andnormetanephrine
excretion rates. Vitamin D does not reverse the hypertensiongenic
effect in the short term (5 weeks). (A) See Figure 2 legend for de-
scription of periods. All values aremeans of three consecutive daily
measurements during the last 3 days of each period. Recovery
values are from measurements 2 months after week 11 to show
reversibility and with the subjects on regular diet only. *P at least
,0.05 for both intra- and intergroup comparisons. (B) Effect of HP
diet on day and night mean arterial BP and mean pulse rates. *P at
least,0.05 for the comparisons to both baseline and recovery. (C)
Per subject changes in MAP in the HP group. BL, baseline; D3, vi-
tamin D3; HP, HP diet; La, lanthanum; LP, LP diet; MAP, mean ar-
terial pressure; NaCl, sodium chloride; NaP, neutral sodium
phosphate; PTH, parathyroid hormone; RD, regular diet; REC, re-
covery; W6 and W11, week 6 and 11, respectively.
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Althoughnotinvestigatedinthisstudy,anadditionalexplanation
for phosphate-induced autonomic increase in BP is phosphate-
induced arterial or visceral inﬂammation35 resulting in local sym-
pathetic afferent activation.36Humanvascular smoothmuscle cells
when incubated for 9 days in an HP medium produced in-
creased levels of reactive oxygen and nitrogen species as well as
inﬂammatory cytokines (e.g., TNFa, IL6, and ICAM-1), a ﬁnd-
ing not modulated by the presence of physiologic 1,25(OH)2D
concentrations.35 Peripheral vascular or visceral inﬂammation
provides an afferent autonomic signal that can activate efferent/
systemic sympathetic outﬂow.36 Notably, however, we did not ﬁnd
an effect of HP on high-sensitivity C-reactive protein serum con-
centration (Table 6).
The phosphate-induced sympathetic activity in this study
did not induce detectable changes in arterial elasticity as an-
alyzed by PWVand AI, conﬁrming and extending the previous
observation that acute and short-term increases of dietary
phosphate did not affect PWV in non-CKD subjects.35 In con-
trast to the ﬁndings in this chronic study, acute phosphate
loading in humans has been reported to impair endothelial
function by disruption of the nitric oxide pathway.37,38 It is
possible that a more chronic phosphate exposure induces
adaptive or regulatory mechanisms able to restore endothelial
function.
The phosphate-induced increase in BP appears to depend
onchronicityof phosphate loading. In aprevious acute studyof
neutral phosphate loading (intravenously and enterally) for 36
hours, also with appropriate Na load control, we did not detect
signiﬁcant differences in 24-hour BP measurements and pulse
rates during phosphate loading and in the ﬁrst 24 hours there-
after (unpublished data, R. Scanni et al.).17 Thus, delineation
of the exact time course of the hypertensinogenic effect of
dietary phosphate and of increased sympathetic tone may
yield additional insight into the mechanisms involved.
Cardiovascular riskmarkers andmarkers of oxidative stress
(“aging”) were not affected by modulating dietary phosphate
or by the supplementation of vitamin D3. The exception was
the increase of lipid peroxide serum concentration and uri-
nary 8-oxo-2-deoxyguanosine in both LP and HP groups that
could, however, be caused by the increase in sodium intake in
both LP and HP.39
Signiﬁcance of Observed Increase in BP and Pulse Rate
The morbidity and mortality implications of phosphate-
induced BP elevations with a mean increment in SBP of ap-
proximately 4mmHg andDBPof approximately 3mmHg are
substantial. Each 20 mmHg increment in SBP and 10 mmHg
increment in DBP is associated with a doubling in the risk of
death caused by stroke, heart disease, or other vascular dis-
ease.40,41 The general population risk ratio (RR) data for ele-
vated pulse rate are also highly signiﬁcant and independent of
age.36 On the basis of a recent meta-analysis of 1.2 million
persons aged 25–90, the RR for resting pulse rate for both
cardiovascular (CV) and all-cause mortality exhibited a linear
rise for values above 45 beats per minute (bpm) (RR, 1.08,Ta
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1.09 per 10-bpm increment, respectively, P,0.01, each), at-
tributed to sympathetic nervous system activity.42 Thus, al-
though this study lacks middle-aged and elderly subjects that
exhibit the highest CV event rates, strong observational data
support both BP and pulse rate CV morbidity and mortality
effects even for small increments and, where data are available,
across all adult age groups for both sexes.
It is also important to point out that the controlled increase
in phosphate load induced in this study (renal excretion in-
creased from amean of 615 to 1245mg per day, or from 20.5 to
41.5mmol/d, see Table 3) is not excessive, but is well within the
range that a majority of a representative United States general
population consumes each day (National Health And Nutri-
tion Examination Survey III).6
Modulators of Phosphate Homeostasis
FGF-23/PTH/1,25(OH)2D
In response to HP, serum phosphate, PTH, FGF-23, and
a-Klotho and urinary Klotho increased signiﬁcantly, whereas
1,25(OH)2D serum concentrations did not change. After sup-
plementation with 600,000 U vitamin D3, 25(OH)D and 1,25
(OH)2D increased signiﬁcantly suggesting that, at least in part,
D3 period elevations in 1,25(OH)2D during both arms were
driven by rising 25(OH)D levels. PTH and FGF-23 (and serum
and urine Klotho) decreased signiﬁcantly in the D3 period of
HP. PTH stimulates and FGF-23 inhibits 1a hydroxylase and
both 1,25(OH)2D and PTH have been shown to increase
FGF-23.24,25 Thus, under the HP conditions of these experi-
ments, our D3 period results are best explained by a dominant
effect of PTHonFGF-23/Klothobecause FGF-23 and serumand
urine Klotho fell in parallel with falling PTH concentrations,
despite continued HP, a further signiﬁcant increase in plasma
phosphate concentration, and persistently high 1,25(OH)2D
levels. These changes in aggregate lend further support to the
notion that complete adaptation to phosphate loading requires
PTH.17,43
It is possible that the sympathetic activation observed herein is
responsible in part for the FGF-23 increase, because acute dosing
with the b adrenergic agonist, isoproterenol, produced large in-
creases in femur FGF-23 expression and administration of the b
blocker, propranolol, prevented the circadian increase in femur
FGF-23 expression.44 Propranolol pretreatment, however, had
no effect on HP-diet–induced femur FGF-23 expression. The
mechanism of b adrenergic control of FGF-23 production was
attributed to a cAMP response element in the FGF-23 promotor
as assessed in osteoblastic UMR-106 cells.44
Klotho
The hyperphosphatemic increase in serum and urinary Klotho
as well as FGF-23 represent the ﬁrst demonstration in humans
of a phosphate-driven increase inKlotho and suggest that elevated
Klotho levels reﬂect a chronic adaptation to phosphate inasmuch
as acute phosphate loading in humans documented an increase
in serum FGF-23 but found no change in serum Klotho.38
Recombinant Klotho administration to FGF-23 knockout mice
is reported to exhibit a phosphaturic effect,45 albeit with n=4,
raising the possibility that proximal tubule effects of klotho are
not conﬁned to its role as coreceptor withmembrane FGFR1c for
circulating FGF-23 agonism.46 The present results with elevated
Klotho and FGF-23 levels leave open the question as to whether
both of the reported proximal tubule effects of the Klotho re-
sponse to hyperphosphatemia [i.e., phosphaturia and decreased
1,25(OH)2D] are dependent on or independent of increased
FGF-23 in humans. The elevations in serum and urinary Klotho
levels in response to hyperphosphatemia in humans reinforce
the mounting evidence for Klotho’s key role as a homeostatic
phosphatonin and, potentially, for homeostatic beneﬁcial effects
in multiple organs.
The elevation of serum 1,25(OH)2D after D3 administra-
tion did not detectably stimulate intestinal phosphate absorp-
tion inHPand induced only amodest stimulatory effect under
LP conditions. Thus, the effect of vitamin D on intestinal
phosphate absorption in humans is small, compatible with
the small effect found in rats.12
In conclusion, this study demonstrates that chronic, i.e.,
weeks of high dietary phosphate intake as sodium phosphate
increases sympathoadrenergic activity and consequently in-
creases SBP, DBP, and pulse rate in young humans with nor-
mal renal function. Thereby, it provides at least one important
explanation for the association of dietary phosphate intake
and/or plasma phosphate concentrations with increased car-
diovascular morbidity and mortality, irrespective of renal
Table 5. Effects of low (upper panel) and high Pi dietary intake (lower panel) without and with vitamin D3 on parameters of
endothelial function and arterial elasticity
Endothelial and Arterial Parameters Baseline W6 W11 (Plus D3) Recovery
Low Pi dietary intake
Reactive hyperemia index 1.67 (1.30 to 2.04) 1.53 (1.30 to 1.86) 1.76 (1.40 to 2.12) ND
AI, % 210.6 (22.0 to 219.2) 27.4 (22 to 212.8) 210.7 (25.7 to 16.4) ND
PWV, m/s 5.1 (4.4 to 5.8) 5.3 (4.5 to 6.1) 5.1 (4.4 to 5.8) ND
High Pi dietary intake
Reactive hyperemia index 1.93 (1.48 to 2.38) 1.84 (1.60 to 2.08) 1.86 (1.50 to 2.22) 1.92 (1.70 to 2.14)
AI, % 210.1 (22.0 to 18.2) 28.1 (23.2 to 213.0) 24.9 (+1.0 to 10.8) 27.8 (0 to 15.6)
PWV, m/s 5.7 (4.7 to 6.7) 5.8 (4.9 to 6.7) 5.7 (4.8 to 6.6) 5.8 (4.9 to 6.7)
Values are means with 95% CIs in brackets. Recovery measurements (2 mo after the high-Pi plus D3 period+1 week) were only performed in the high-Pi group. D3,
vitamin D3; W, week; Pi, phosphorus.
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function. These conclusions, although of high public health
importance, require support of larger studies in more diverse
populations.
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